Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

6-miesięczne i 18-miesięczne randomizowane podwójne badanie oceniające bezpieczeństwo i skuteczność Buntanetap u osób z wczesnym AD (DUET-AD)

16 listopada 2026 zaktualizowane przez: Annovis Bio Inc.

Prospektywne, 6-miesięczne i 18-miesięczne, randomizowane, kontrolowane placebo, podwójnie ślepe badanie kliniczne z podwójną ślepą próbą badające skuteczność i bezpieczeństwo stosowania Buntanetap w leczeniu osób z wczesną chorobą Alzheimera

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:

  • Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
  • Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
  • What medical issues do participants have, if any, when taking buntanetap/Posiphen?

Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.

Participants will:

  • Take buntanetap/Posiphen or a placebo every day for 18 months
  • Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
  • Complete pre- and post-clinic visit phone calls

Przegląd badań

Status

Aktywny, nie rekrutujący

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

861

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Arizona
      • Chandler, Arizona, Stany Zjednoczone, 85286
        • MD First Research
      • Phoenix, Arizona, Stany Zjednoczone, 85004
        • Xenoscience
      • Scottsdale, Arizona, Stany Zjednoczone, 85258
        • Clinical Endpoints
    • California
      • Anaheim, California, Stany Zjednoczone, 92805
        • Advanced Research Center
      • Canoga Park, California, Stany Zjednoczone, 91303
        • Hope Clinical Research
      • Imperial, California, Stany Zjednoczone, 92251
        • Sun Valley Research
      • Los Angeles, California, Stany Zjednoczone, 90095
        • Mary S. Easton Center for Alzheimer's Research and Care, UCLA
      • Sacramento, California, Stany Zjednoczone, 95816
        • UC Davis Alzheimer's Disease Research Center
      • San Marcos, California, Stany Zjednoczone, 92069
        • The Neuron Clinic
    • Colorado
      • Basalt, Colorado, Stany Zjednoczone, 81621
        • Mountain Neurological Center
      • Englewood, Colorado, Stany Zjednoczone, 80113
        • CenExel Rocky Mountain
    • Connecticut
      • Norwalk, Connecticut, Stany Zjednoczone, 06851
        • Research Center for Clinical Trials
    • Florida
      • Aventura, Florida, Stany Zjednoczone, 33180
        • Visionary Investigators Network
      • Boca Raton, Florida, Stany Zjednoczone, 33487
        • SFM Clinical Research
      • Clermont, Florida, Stany Zjednoczone, 34711
        • K2 Medical Research
      • Daytona Beach, Florida, Stany Zjednoczone, 32114
        • K2 Medical Research Daytona
      • Fort Myers, Florida, Stany Zjednoczone, 33912
        • Neuropsychiatric Research Center
      • Hallandale, Florida, Stany Zjednoczone, 33009
        • Velocity Clinical
      • Jacksonville, Florida, Stany Zjednoczone, 32216
        • Jacksonville Center for Clinical Research
      • Lady Lake, Florida, Stany Zjednoczone, 32159
        • K2 Medical Research
      • Lake Worth, Florida, Stany Zjednoczone, 33462
        • Headlands Research JEM
      • Lakeland, Florida, Stany Zjednoczone, 33803
        • Accel Research Sites Lakeland (Alcanza)
      • Maitland, Florida, Stany Zjednoczone, 32751
        • K2 Medical Research
      • Melbourne, Florida, Stany Zjednoczone, 32940
        • ClinCloud Clinical Research
      • Merritt Island, Florida, Stany Zjednoczone, 32952
        • Flourish Research/Merritt Island Medical Research
      • Miami, Florida, Stany Zjednoczone, 33137
        • Miami Jewish Health
      • Naples, Florida, Stany Zjednoczone, 34102
        • Aqualane Clinical Research
      • New Port Richey, Florida, Stany Zjednoczone, 34652
        • Suncoast Clinical Research
      • Orlando, Florida, Stany Zjednoczone, 32832
        • Conquest Research
      • Tampa, Florida, Stany Zjednoczone, 33609
        • Axiom Brain Health, LLC
      • Winter Park, Florida, Stany Zjednoczone, 32789
        • Conquest Research
    • Georgia
      • Decatur, Georgia, Stany Zjednoczone, 30030
        • Accel Neurosciences
      • Gainesville, Georgia, Stany Zjednoczone, 30501
        • CARE (Center for Advanced Research & Education)
    • Hawaii
      • Honolulu, Hawaii, Stany Zjednoczone, 96817
        • Hawaii Pacific Neuroscience
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60612
        • Rush University Medical Center
      • Chicago, Illinois, Stany Zjednoczone, 60611
        • Re:Cognition Chicago
      • Chicago, Illinois, Stany Zjednoczone, 60618
        • Charter Research Chicago
      • Chicago, Illinois, Stany Zjednoczone, 60640
        • Great Lakes Clinical Trials/Flourish Research
      • Springfield, Illinois, Stany Zjednoczone, 62702
        • Southern Illinois University
    • Indiana
      • Indianaopolis, Indiana, Stany Zjednoczone, 46256
        • JWM Research
    • Kansas
      • Wichita, Kansas, Stany Zjednoczone, 37214
        • Ascension via Christi Research
    • Louisiana
      • Metairie, Louisiana, Stany Zjednoczone, 70006
        • Tandem Intermediate
    • Maryland
      • Pikesville, Maryland, Stany Zjednoczone, 21208
        • Headlands Research Pharmasite
    • Massachusetts
      • Foxborough, Massachusetts, Stany Zjednoczone, 02035
        • Neurology Center of New England, PC
      • Plymouth, Massachusetts, Stany Zjednoczone, 02360
        • Headlands Research Easter Massachusetts
      • Russells Mills, Massachusetts, Stany Zjednoczone, 02747
        • Mayflower Clinical
      • Springfield, Massachusetts, Stany Zjednoczone, 01103
        • Elixia MA
    • Michigan
      • Farmington Hills, Michigan, Stany Zjednoczone, 48334
        • Quest Research Institute
    • Mississippi
      • Flowood, Mississippi, Stany Zjednoczone, 39232
        • Precise Research Center
    • Missouri
      • Chesterfield, Missouri, Stany Zjednoczone, 63005
        • Clinical Research Professionals - Headlands Research
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89121
        • Oasis Clinical Trials LLC
    • New Jersey
      • Toms River, New Jersey, Stany Zjednoczone, 08755
        • Cenexel Advanced Medical Research of New Jersey (AMRI)
      • West Long Branch, New Jersey, Stany Zjednoczone, 07764
        • Advanced Clinical Institute
    • New York
      • Amherst, New York, Stany Zjednoczone, 14226
        • Dent Neurologic Institute
      • Brooklyn, New York, Stany Zjednoczone, 11235
        • SPRI
      • Lake Success, New York, Stany Zjednoczone, 11042
        • Neurological Associates of Long Island
      • New York, New York, Stany Zjednoczone, 10003
        • New York Neurology Associates
      • Staten Island, New York, Stany Zjednoczone, 10314
        • Richmond Behavioral Associates
      • Syracuse, New York, Stany Zjednoczone, 13210
        • Ichor Research
    • North Carolina
      • Durham, North Carolina, Stany Zjednoczone, 27705
        • Duke University
      • Matthews, North Carolina, Stany Zjednoczone, 28105
        • AMC Research/Flourish Research
    • Ohio
      • Beavercreek, Ohio, Stany Zjednoczone, 45432
        • American Clinical Research Center
      • Centerville, Ohio, Stany Zjednoczone, 45459
        • Valley Medical Research
      • Independence, Ohio, Stany Zjednoczone, 44131
        • Insight Clinical Trials
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97210
        • Summit Headlands
    • Pennsylvania
      • Media, Pennsylvania, Stany Zjednoczone, 19063
        • Suburban Research Associates
      • Plymouth Meeting, Pennsylvania, Stany Zjednoczone, 19462
        • K2 Keystone
    • Rhode Island
      • East Providence, Rhode Island, Stany Zjednoczone, 02914
        • Rhode Island Mood and Memory Research Institute
    • South Carolina
      • Summerville, South Carolina, Stany Zjednoczone, 29486
        • Palmetto Primary Care & Specialty Physicians
    • Tennessee
      • Cordova, Tennessee, Stany Zjednoczone, 38018
        • Neurology Clinic, P.C.
      • Nashville, Tennessee, Stany Zjednoczone, 37204
        • K2 Medical Research Nashville
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78757
        • Senior Adults Specialty Research
      • Houston, Texas, Stany Zjednoczone, 77094
        • NeuroMind Clinical Trials
      • Round Rock, Texas, Stany Zjednoczone, 78681
        • Central Texas Neurology Associates
      • Wichita Falls, Texas, Stany Zjednoczone, 76309
        • Grayline Research Center
    • Vermont
      • Bennington, Vermont, Stany Zjednoczone, 05201
        • Memory Clinic, Inc.
    • Virginia
      • Arlington, Virginia, Stany Zjednoczone, 22205
        • Sana Research
      • Fairfax, Virginia, Stany Zjednoczone, 22031
        • Re:Cognition Fairfax

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

55 lat do 85 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.

  2. Male or female, aged 55 - 85 years.

  3. MMSE 20-28 at screening and baseline.

  4. CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.

  5. Positive for amyloid beta as defined by plasma p-tau217 level at screening.

  6. Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.

  7. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.

  8. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    • Intrauterine device (IUD),

    • Intrauterine hormone-releasing system (IUS),

    • Bilateral tubal occlusion,

    • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),

    • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
  9. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    • IUD,
    • IUS,
    • Bilateral tubal occlusion.
  10. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent. At re-consent, a legally authorized representative may co-sign if participants do not meet the general cognition and functional performance needed in the opinion of the investigator.

  11. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.

  12. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.

    • Cholinesterase inhibitors and/or memantine medication,
    • Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
    • Mood-stabilizing psychotropic agents including, but not limited to, lithium.
  13. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  14. Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.

Exclusion Criteria:

  1. Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.

  3. History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage (>5) or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).

  5. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.

  6. Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

  7. Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.

  8. Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <50 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).

  9. Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.

  10. Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  11. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  12. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.

  13. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  14. Participants with learning disability or developmental delay.

  15. Participants whom the PI deems to be otherwise ineligible.

  16. Participants with a known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified Microcrystalline Cellulose
    • Dibasic Calcium Phosphate Dihydrate
    • Mannitol
    • Stearic Acid
    • Hypromellosee (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  17. Participant is currently pregnant, breast-feeding, and/or lactating.

  18. Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.

  19. Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Placebo

Placebo capsule by mouth once daily for 18 months

Eksperymentalny: buntanetap

30mg capsule by mouth once daily for 18 months

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Ramy czasowe: From screening to 6-month readout, to end of treatment at 18 months.

ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment.

From screening to 6-month readout, to end of treatment at 18 months.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Ramy czasowe: From screening to 6-month readout, to end of treatment at 18 months.

The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function.

From screening to 6-month readout, to end of treatment at 18 months.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

4 lutego 2025

Zakończenie podstawowe (Szacowany)

1 grudnia 2027

Ukończenie studiów (Szacowany)

1 czerwca 2028

Daty rejestracji na studia

Pierwszy przesłany

26 listopada 2024

Pierwszy przesłany, który spełnia kryteria kontroli jakości

26 listopada 2024

Pierwszy wysłany (Rzeczywisty)

29 listopada 2024

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

19 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

16 listopada 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIEZDECYDOWANY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj